Loading…
← CockpitCompetitor Analysis › 605507.SS Guobang Pharma Ltd. Class AOpen in the cockpit ↗

Guobang Pharma Ltd. Class A605507.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese maker of antibiotic active pharmaceutical ingredients, used in both human and animal-health medicines.

Momentum leader 87
Mkt cap
$1.82B
US dollars, full cap
Free float
33%
of shares outstanding
$/day
$10.2M
20-day average traded
Fwd P/E
15.7×
forward earnings
ROIC−WACC
+5.4 pp
WACC 5.0%
Hurdle
-13 pp
Req g minus delivered
Next earnings
145 days
12 Apr 2027
Close · CNYCN¥15.60
1D-1.4%
1W+1.4%
1M+0.5%
3M-0.6%
6M-6.3%
YTD-11.9%
1Y-1.8%
ATR %3.0%
52w lowhigh27.1% off high

What Guobang Pharma does

Chinese maker of antibiotic active pharmaceutical ingredients, used in both human and animal-health medicines.

Products and services

  • Antibiotic APIs
  • Animal-health antibiotic products

Customers

  • Pharma/animal-health formulators

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Antibiotic API manufacturing

What could go right

  • Antibiotic/animal-health API demand

What could go wrong

  • API price competition
  • Environmental compliance costs

Moat: narrow (scale, regulatory licence). Scale antibiotic API production with environmental/regulatory compliance built up over years.

Headquarters: China · Employees: 4,251

Named competitors

Guobang Pharma at a glance

Size Guobang Pharma (605507.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.82B, the 1266th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.60 on 18 Nov 2026.

Performance Over six months the shares fell 6.3%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 3.2% over the last twelve months (peer median +7.8%); the operating margin is 12.2% (peer median 15.0%).

Valuation It trades at 15.7× forward earnings against a peer median of 19.4× (8th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026605507.SS 97Peer median 92
Six months, rebased to 100: Guobang Pharma against the median of its 20 peers (local-currency closes).

Guobang Pharma financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.13BCN¥5.99BCN¥5.87BCN¥5.34BCN¥5.70B
Revenue growth—+2%+10%-6%—
Gross profitCN¥1.73BCN¥1.46BCN¥1.37BCN¥1.17BCN¥1.49B
EBITDAn/aCN¥1.39BCN¥1.27BCN¥949MCN¥1.21B
Net incomeCN¥622MCN¥821MCN¥782MCN¥612MCN¥921M
Free cash flowCN¥569MCN¥282MCN¥287M-CN¥232MCN¥214M
Capital expenditureCN¥360MCN¥278MCN¥419MCN¥748MCN¥803M
Total debtCN¥2.01BCN¥1.66BCN¥1.99BCN¥2.06BCN¥1.21B

Quarterly statements and history in the cockpit →

Guobang Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%-10%0%+10%300573000028ZYMERARE301015002399DMP3933000908ETON600664COHANCEAGIO300009PFIZERALIVUSSHILPAMED0512605507.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Guobang Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×300573000028ZYMERARE301015DMP3933ETONCOHANCEPFIZERSHILPAMEDNATCOPHARM605507.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guobang Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%300573000028002399ETONALIVUS605507.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guobang Pharma is the large dot.

Guobang Pharma competitors and peer comparison

Head to head with its named competitors (605507.SS vs 600664.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Guobang Pharma 605507.SS$1.82B-6%+3%12%15.7×-6.0%
Harbin Pharmaceutical 600664.SS$1.78B+32%+2%5%19.7×-5.3%

How Guobang Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guobang Pharma against its 20 peers (data as of 18 Nov 2026)
Measure605507.SSPeer medianRank in peer set
1-month return+0.5%+0.3%11th highest of 21
6-month return-6.3%-10.4%10th highest of 21
Distance from 52-week high-27.1%-32.8%8th highest of 21
Revenue growth (TTM)+3.2%+7.8%9th lowest of 21
Operating margin12.2%15.0%10th lowest of 21
Forward P/E15.7×19.4×8th cheapest of 19
Growth the price implies (Req g, 7 yrs)-6.0%3.3%2nd least demanding of 15
Growth delivered (Del g)+7.4%+8.1%6th lowest of 15
Hurdle (Req g minus delivered)-13.4 pp-9.0 pp6th least demanding of 15
ROIC minus cost of capital+5.4 pp+0.1 pp8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%

Questions

Who are Guobang Pharma's main competitors?
Named competitors: Harbin Pharmaceutical Group (600664.SS). The cockpit's measured peer set (industry) also includes Shenyang Xingqi Pharmaceutical (300573.SZ), China National Accord Medicines (000028.SZ), Zymeworks (ZYME), Ultragenyx Pharmaceutical (RARE), Qingdao Baheal Medical (301015.SZ), Shenzhen Hepalink Pharmaceutical (002399.SZ).
Is Guobang Pharma expensive compared with its peers?
On forward p/e it trades at 15.7× against a peer median of 19.4×, 8th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Guobang Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -6.3% against -10.4% for the median peer; over one year -1.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.